CVS Health Corporation (CVS)
Major CVS shareholder plans activist push, will meet with management, sources say
Glenview Capital has amassed a sizable stake in CVS Health and plans to meet with the company's top executives to lay out its plan for value creation, according to people familiar with the matter. The proposal is seen as a precursor to an activist push at the company, the people said.
Glenview Capital Plans Push for Changes at CVS
The hedge fund has taken a large position in the healthcare company, which has seen its shares fall 24% this year to date
Glenview plans activist stance in push for changes at CVS, WSJ reports
Healthcare-focused Glenview Capital Management has established a large position in CVS Health and will meet top executives at the struggling healthcare company on Monday to propose ways it can improve its operations, The Wall Street Journal reported on Sunday.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, CVS Health (CVS) stood at $58.64, denoting a +0.96% change from the preceding trading day.
‘Can't afford health insurance': California CVS workers take strike vote
More than 7,000 workers to hold strike vote this week amid accusations of staff shortages and expensive healthcare
Is CVS Health Stock a Buy?
CVS Health's Medicare Advantage business has been encountering headwinds. The market also isn't impressed with the company's financial results and guidance.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
CVS Health Corporation Is Being Sued For Securities Law Violations And The Schall Law Firm Invites Investor Participation
LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CVS's Guide May Have Reached 'Kitchen Sink' Point
Despite deteriorating fundamentals and bad press, I bought a half-sized position in CVS due to its historical and relative cheapness, attractive yield, and potential for recovery. CVS trades below 9x forward PE, indicating it's priced for further deterioration, but it's historically and relatively cheap compared to peers like CI and UNH. CVS offers a 4.6% yield, making it an attractive income security, especially compared to treasury rates and other high-yield securities.
A Securities Fraud Lawsuit Has Been Filed Against CVS Health Corporation And Shareholders With Losses Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.
